Identification and validation of the VEGF/p38MAPK/HSP27 pro-tumor inflammatory pathway: screening of active components from Patrinia villosa and evaluation of their drug-likeness
This study provides theoretical and experimental evidence for pharmacological targets involved in pro-tumor inflammation in CRC. The findings offer valuable insights for developing novel anti-inflammatory therapeutics targeting the VEGF/p38MAPK/HSP27 signaling pathway.
Authors
- Xinxin Yang (ORCID: https://orcid.org/0000-0002-2024-4307)
- Xiansheng Meng (ORCID: https://orcid.org/0000-0003-2814-4615)
- Yongrui Bao (ORCID: https://orcid.org/0000-0003-0588-2113)
- Ju Yang (ORCID: https://orcid.org/0000-0001-5305-7893)
- Shuai Wang (ORCID: https://orcid.org/0000-0002-8895-5199)
- Xiaochen Li (ORCID: https://orcid.org/0000-0001-7833-8042)
- Tianjiao Li (ORCID: https://orcid.org/0000-0002-3557-5715)
Institutions
- Shenyang Pharmaceutical University (CN)
- Liaoning University of Traditional Chinese Medicine (CN)
- Shenyang Center for Disease Control and Prevention (CN)
- Institute of Modern Physics (CN)
- Shenyang 242 Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1631031
- Primary Topic
- Biomarkers in Disease Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00